Jenn Buechel
President bij Delfi Diagnostics, Inc.
Profiel
Jenn Buechel is currently the Director at MOBILion Systems, Inc., a Member at Aspen Global Leadership Network, and the President & Chief Operating Officer at Delfi Diagnostics, Inc. She has a graduate degree and an MBA from Stanford University, as well as an undergraduate degree from Queen's University.
Actieve functies van Jenn Buechel
| Bedrijven | Functie | Begin |
|---|---|---|
Delfi Diagnostics, Inc.
 Delfi Diagnostics, Inc. Medical/Nursing ServicesHealth Services Delfi Diagnostics, Inc. engages in the development of blood test for detection and interception of cancer. It uses artificial intelligence and whole genome sequencing to detect patterns of DNA fragmentation in the blood of patients with cancer. The company is headquartered in Baltimore, MD. | President | 23-02-2023 |
MOBILion Systems, Inc.
 MOBILion Systems, Inc. Packaged SoftwareTechnology Services MOBILion Systems, Inc. offers paradigm-shifting platform technology. It will Develop a cost effective analytical system with a small footprint, high throughput, ultra-high sensitivity and selectivity enabling use in commercial applications unattainable by conventional ion mobility separation devices. The company was founded in 2015 and is headquartered in , Chadds Ford, PA. | Director/Board Member | 26-07-2022 |
| Aspen Global Leadership Network | Corporate Officer/Principal | - |
Opleiding van Jenn Buechel
| Stanford University | Graduate Degree |
| Queen's University | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 3 |
|---|---|
MOBILion Systems, Inc.
MOBILion Systems, Inc. Packaged SoftwareTechnology Services MOBILion Systems, Inc. offers paradigm-shifting platform technology. It will Develop a cost effective analytical system with a small footprint, high throughput, ultra-high sensitivity and selectivity enabling use in commercial applications unattainable by conventional ion mobility separation devices. The company was founded in 2015 and is headquartered in , Chadds Ford, PA. | Technology Services |
| Aspen Global Leadership Network | |
Delfi Diagnostics, Inc.
Delfi Diagnostics, Inc. Medical/Nursing ServicesHealth Services Delfi Diagnostics, Inc. engages in the development of blood test for detection and interception of cancer. It uses artificial intelligence and whole genome sequencing to detect patterns of DNA fragmentation in the blood of patients with cancer. The company is headquartered in Baltimore, MD. | Health Services |
